LAVA Therapeutics (LVTX)

• Market cap: $25.6M
• 1 day: -0.87%
• 5 days: -6.23%
• 1 month: -39.43%
• 3 months: -42.30%
• 6 months: -47.85%
• Year to date: -44.27%
• 1 year: -34.99%
• 5 years: -93.18%
• 10 years: -93.18%

About: LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.

Employees: 37

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

11% more funds holding

Funds holding: 19 [Q2] → 21 (+2) [Q3]

0.63% less ownership

Funds ownership: 14.36% [Q2] → 13.73% (-0.63%) [Q3]

12% less capital invested

Capital invested by funds: $6.79M [Q2] → $5.96M (-$835K) [Q3]

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 105% upside
• Avg. target: $3.33 242% upside
• High target: $6 515% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

HC Wainwright & Co. Arthur He 30% 1-year accuracy 11 / 37 met price target	105% upside $2	Buy Maintained	20 Dec 2024
Leerink Partners Daina Graybosch 0% 1-year accuracy 0 / 1 met price target	105% upside $2	Market Perform Downgraded	12 Dec 2024
JMP Securities Reni Benjamin 8% 1-year accuracy 3 / 36 met price target	515% upside $6	Market Perform Downgraded	11 Dec 2024